Introduction
Retroviral activation of the ecotropic viral integration site 1 (Evi1) results in leukemia in mice (Morishita et al., 1988) . Evi1 activation has been implicated in hematopoietic malignancies in humans (Bartholomew and Ihle, 1991; Ogawa et al., 1996) , and the oncogenic role of Evi1 has been studied extensively in myeloid and lymphoid leukemia. Evi1 is located on human chromosome 3q26, and the 3q25-27 region is amplified in cancer of the cervix (Sugita et al., 2000) , ovary (Sonoda et al., 1997) , lung (Brass et al., 1996; Racz et al., 1999; Imoto et al., 2001) , head and neck (Bergamo et al., 2000) , and prostate (Sattler et al., 2000) . The relationship between 3q26 amplification and Evi1 expression has not been systematically studied, although it is known that Evi1 is overexpressed in some ovarian cancers (Brooks et al., 1996) . These data suggest that Evi1 may play a role in the initiation and/or progression of solid tumors, as well as hematopoietic malignancies.
Evi1 is a transcriptional repressor (Tanaka et al., 1994; Hirai, 1999; Mochizuki et al., 2000; Palmer et al., 2001; Wakefield and Roberts, 2002) , which inhibits TGFb signaling by binding Smad3 and recruiting corepressors of the CtBP family (Kurokawa et al., 1998; Izutsu et al., 2001; Alliston et al., 2005) . CtBP recruits histone deacylases, and thereby converts Smad3 from a TGFb-responsive transcriptional activator to a transcriptional repressor (Izutsu et al., 2001; Alliston et al., 2005) . The ability of Evi1 to transform hematopoietic cells may result, at least in part, from the ability to inhibit Smad3-mediated transactivation of gene expression, although Evi1 fusion proteins and alternatively spliced forms Evi1 may have different effects on TGFb signaling (Sood et al., 1999) .
TGFb is an important regulator of proliferation, migration, differentiation, and death of epithelial cells, and loss of TGFb-mediated growth control is thought to be an obligatory step during colon cancer progression (Roman et al., 2001) . Loss of TGFb responsiveness during colon carcinogenesis has been associated with genetic and epigenetic inactivation of the TGFb type II receptor Parsons et al., 1995) , Smad mutations (Riggins et al., 1997) , oncogenic activation of K-Ras (Higashidani et al., 2003) , and induction of protein kinase C-beta II (Murray et al., 2002) . However, the possible role of Evi1 in TGFb signaling in colon cancer is poorly understood. In this report, we assessed the role of Evi1 in TGFb-mediated signaling in non-transformed intestinal epithelial cells. Our data demonstrate that Evi1 inhibits some, but not all TGFb responses. The most significant effect of Evi1 appears to be suppression of TGFb-mediated apoptosis. Our results also reveal that Evi1 functions as a survival gene in colon cancer cells and plays a key role in resistance to chemotherapeutic drugs such as taxol.
Results

Evi1 inhibits transactivation of TGFb target genes in RIE cells
Evi1 is known to inhibit Smad3-dependent transactivation in hematopoietic cells (Kurokawa et al., 1998) . Our first objective was to confirm this response in nontransformed intestinal epithelial cells. RIE-1 cells were transiently cotransfected with an Evi1 expression vector (pRK5/Evi1) plus the 3TP/luc TGFb reporter construct (Wrana et al., 1994) . As shown in Figure 1a , RIE-1 cells exhibited a robust transcriptional response to TGFb when the 3TP/luc reporter was cotransfected with an 'empty' pRK5 expression vector. Cotransfection of the pRK5/Evi1 expression vector profoundly inhibited TGFb-dependent transactivation of 3TP/luc in the transient transfection assay. The magnitude of inhibition (75%) was similar to that observed when TGFbmediated transcriptional activity was blocked by expression of dominant-negative Smad3 (89%), indicating that Evi1 attenuates TGFb-mediated, Smad-dependent promoter transactivation in intestinal epithelial cells.
Interpretation of transient transfection data is often confounded by the fact that supra-physiological levels of expression of putative transcription factors can be achieved, leading to squelching artifacts that may not prevail under more physiological conditions. To circumvent these potential problems, we constructed a cell line that stably expresses Evi1. As a control, we constructed an RIE-1 derivative that was stably transformed to puromycin resistance with the pBabe/ puro-3 retrovirus (RIE/pBabe). As shown in Figure 1b , Evi1 protein was not detectable in RIE/pBabe but was stably expressed in RIE/Evi1 cells. TGFb is known to downregulate the TGFb type II receptor (TBRII), as illustrated by a decrease in TBRII expression in TGFbtreated RIE/pBabe cells, relative to control RIE/pBabe cells (Figure 1b ). Evi1 expression had no effect on ligand-mediated downregulation of TBRII, indicating that the early steps in activation of TGFb signaling are intact in RIE/Evi1 cells. This conclusion was confirmed by the observation that TGFb-dependent phosphorylation of Smad2 was not inhibited by Evi1 (Figure 1b) . Furthermore, Evi1 had no effect on Smad2 or Smad3 expression in RIE cells.
Although RIE/Evi1 cells retain the ability to activate the TGFb receptor complex and phosphorylate Smads in response to TGFb, these cells are defective in activation of classical Smad3-responsive genes, such as PAI1 (Figure 1c ), demonstrating that this oncogene blocks TGFb-mediated induction of endogenous genes, as well as transiently transfected reporters. The magnitude of inhibition by Evi1 (93%) was comparable to that observed in RIE-1/dnSmad3 cells (97% in Figure 1c Evi1 has no effect on TGFb-mediated EMT TGFb regulates cell motility during organogenesis (Hay, 1995 ) , and it is believed that regulation of cell motility is involved in tumor promotion by TGFb (Akhurst and Derynck, 2001; Wakefield and Roberts, 2002) . Changes in motility of epithelial cells are associated with a characteristic morphological transition, known as EMT, which is accompanied by changes in integrin/focal adhesion kinase signaling, as well as changes in the actin cytoskeleton. In RIE-1 cells, one of the earliest manifestations of EMT is induction of integrina1 mRNA. As shown in Figure 2a , integrina1 mRNA abundance increased four-to five-fold within 8 h after addition of TGFb to RIE/pBabe cells. The induction of integrina1 mRNA in TGFb-treated RIE/Evi1 cells was comparable to that observed in RIE/pBabe cells. These results indicate that the early effects of TGFb on integrin signaling are intact in RIE/Evi1 cells. During EMT, TGFb induces changes in focal adhesion activity. As shown in Figure 2b , TGFb induces the focal adhesion protein paxillin and stimulates tyrosine phosphorylation of paxillin by focal adhesion kinase in RIE/pBabe cells. Paxillin was induced by TGFb in RIE/Evi1 cells, and TGFb promoted tyrosine phosphorylation of paxillin in RIE/Evi1 cells. Dominant-negative Smad3 (dnSmad3) blocks almost all known TGFb signaling events, and therefore was used as a negative control. As shown in Figure 2a and b, dnSmad3 inhibited induction of integrina1 and paxillin, as well as stimulation of paxillin phosphorylation in TGFb-treated cells.
The morphological hallmark of EMT is formation of actin stress fibers. As shown in Figure 2c , addition of TGFb to RIE/pBabe cells induced a characteristic EMT response with formation of prominent actin stress fibers. Stress fiber formation in TGFb-treated cells was not inhibited by Evi1. However, induction of actin stress fibers was inhibited in TGFb-treated cells that express dnSmad3 (RIE/dnSmad3, consistent with the observation that dnSmad3 blocks activation of integrin signaling and focal adhesion kinase. These data indicate that even though Evi1 blocks TGFb-dependent activation of some classical target genes such as PAI1, induction of other genes, such as integrina1 and paxillin is not affected by Evi1, and Evi1 does not block TGFbmediated EMT in intestinal epithelial cells.
Evi1 does not block TGFb-mediated growth inhibition in RIE cells
Inhibition of epithelial cell proliferation is thought to be one of the principal physiological roles of TGFb, and rat intestinal epithelial cells such as RIE-1 and IEC6 are exquisitely sensitive to TGFb-mediated growth inhibition (Ko et al., 1994) . In such cells, TGFb-mediated growth inhibition is due to inhibition of cyclin D1 expression (Ko et al., 1995 (Ko et al., , 1998 
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Figure 2 Evi1 does not inhibit TGFb-mediated epithelial to mesenchymal transition in RIE cells. (a) RIE/pBabe, RIE/Evi1, or RIE/snSmad3 cells were treated with 3 ng/ml TGF-b1 for 8 h. RNA was extracted and integrina1 mRNA was measured by QPCR. Data were normalized to GAPDH and calibrated to expression of integrina1 in control RIE/pBabe cells, which was set to 1.0. (b) Cells were treated with 3 ng/ml TGF-b1 for 24 h. Protein was extracted and immunoblotted using specific antibodies for paxillin or phospho-paxillin. (c) Cells were treated with 3 ng/ml TGF-b1 for 24 h. After fixation, cells were stained with Texas Red phalloidin to visualize the actin cytoskeleton.
Evi1 is a survival factor in intestinal epithelial cells Y Liu et al RIE/Evi1 cells, suggesting that Evi1 may not affect TGFb-mediated G1 arrest in RIE cells. Therefore, we measured culture growth rates of RIE/pBabe, RIE/Evi1, and RIE/dnSmad3 cells ( Figure 3c ). Addition of TGFb inhibited proliferation of RIE/pBabe cells, as previously reported (Ko et al., 1994) , whereas TGFb did not inhibit proliferation of RIE/dnSmad3 cells. Evi1 did not block TGFb-mediated growth inhibition of RIE/Evi1 cells, consistent with the effects of TGFb on cyclin D1 expression in RIE/Evi1 cells.
The results shown in Figure 3c were confirmed using flow cytometry to measure DNA content in TGFbtreated RIE/pBabe and RIE/Evi1 cells, as shown in Table 2 . TGFb treatment of RIE/pBabe cells caused a significant increase G1-phase cells (Po0.01) with a concomitant decrease in S-phase cells (Po0.001). Cell cycle distribution of RIE/Evi1 cells was not significantly different from that of RIE/pBabe cells, consistent with the observation that the population doubling times of these cultures are similar. Furthermore, TGFb caused a significant increase in REI/Evi1 cells in G1 phase (Po0.03) with a corresponding decrease in S-phase cells (Po0.006). Thus, in all respects, the antiproliferative effects of TGFb are identical in RIE/pBabe and RIE/Evi1 cells.
Evi1 inhibits TGFb-mediated apoptosis in intestinal epithelial cells
TGFb-mediated inhibition of RIE cell growth in culture is due, in part, to induction of apoptosis (Conery et al., 2004 ) . As shown in Figure 4a , TGFb treatment of RIE/ pBabe cells resulted in a decrease in total caspase 3 and a corresponding increase in cleaved caspase 3 (Casp3*). Likewise, TGFb treatment of RIE/pBabe cells resulted in a decrease in total poly(ADP-ribose) polymerase (PARP) with a corresponding increase in cleaved PARP (PARP*), as shown in Figure 4b . Both Evi1 and dnSmad3 blocked TGFb-mediated cleavage of caspase 3 ( Figure 4a ) and PARP (Figure 4b ), indicating that Evi1 inhibits TGFb-mediated apoptosis. This result was confirmed by measuring release of nuclear histones ( Figure 4c ). Nuclear histone release was stimulated by TGFb in RIE/pBabe cells. However, both basal and TGFb-induced release of nuclear histones were inhibited in RIE/Evi1 cells relative to RIE/pBabe. We have previously reported that induction of apoptosis in RIE cells involves Smad3 (Conery et al., 2004) , and, consistent with these data, RIE/dnSmad3 cells are resistant to induction of nuclear histone release by TGFb (Figure 4c ). However, unlike Evi1, dnSmad3 had no effect on basal apoptosis in RIE cells.
The observation that Evi1 caused a significant reduction in basal apoptosis in RIE cells suggested that this oncogene might have a general affect on cellular survival. To test this hypothesis, we measured apoptosis in cells treated with taxol (paclitaxel). Addition of 10 nM taxol caused release of nuclear histones in RIE/pBabe cells (Figure 4c ). Although RIE/dnSmad3 cells were insensitive to TGFb-mediated apoptosis, these cells were as sensitive to taxol as RIE/pBabe cells. However, Figure 3 Evi1 does not inhibit TGFb-mediated growth inhibition in RIE cells. Cells were treated with 3 ng/ml TGF-b1 for 24 h and RNA and protein were extracted. (a) QPCR was used to measure cyclin D1 mRNA abundance. Cyclin D1 expression was calibrated to control RIE/pBabe cells, in which expression was set to 1.0. The bars represent the mean and s.d. of three replicates. (b) western blotting was used to measure cyclin D1 protein in the extracts described above. (c) Culture growth was measured by counting cell number in control and TGFb-treated cultures. Control culture growth is shown in filled circles, whereas growth in 3 ng/ml TGF-b1 is shown in open circles. Each point represents the mean and s.d. for three replicate samples.
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RIE/Evi1 cells were resistant to taxol-mediated apoptosis ( Figure 4c ). These data were confirmed by measuring nuclear histone release as a function of time and taxol concentration ( Figure 4d ). RIE/pBabe cells are exquisitely sensitive to taxol, exhibiting almost complete cell death within 16 h after addition of 10 nM taxol ( Figure 4d ). RIE/Evi1 cells were significantly more resistant to taxol-mediated cell death. These data indicate that Evi1 protects RIE cells from cell death mediated by physiological mediators such as TGFb or by cytotoxic drugs such as taxol.
Evi1 suppresses apoptosis by a phosphoinositide-3-kinase (PI3K)/AKT-dependent mechanism dnSmad3 blocks TGFb-mediated apoptosis, suggesting that the antiapoptotic effects of Evi1 may be mediated by inhibition of Smad signaling. However, there is no known role of Smads in taxol-induced apoptosis. Since Evi1 inhibits taxol-dependent cell death, Evi1 inhibition of taxol-mediated cell death may be unrelated to inhibition of Smad3 signaling. Therefore, we measured the activity of other signal transduction pathways that have been implicated in TGFb signaling and/or apoptosis. Both p38 MAPK and JNK are known to be regulated by TGFb under some circumstances and both have been implicated in apoptosis. Evi1 had no effect on the activity of p38 MAPK, as measured by the phosphorylation state of this enzyme (Figure 5a ). Evi1 is known to inhibit JNK activity (Kurokawa et al., 2000) . However, phosphorylation of JNK is below the limits of detection in RIE cells, and it was not possible to determine if JNK phosphorylation is affected by Evi1. Conversely, we observed a significant increase in phosphorylation of ERK1/2 and AKT in RIE/Evi1 cells, compared to RIE/pBabe. TGFb had little or no effect on phosphorylation of ERK1/2 or AKT ( Figure 5b ). (Although there appears to be less phospho-ERK1/2 in TGFb-treated RIE/Evi1 cells, this apparent decrease is due to loading, as evidenced by reduced total ERK1/2 in this lane.) The observation that TGFb does not regulate ERK1/2 or AKT phosphorylation in these cells indicates that differences in basal ERK1/2 and AKT phosphorylation in RIE/pBabe and RIE/Evi1 cells are not due to changes in TGFb signaling. Next, we used a panel of inhibitors to determine if any of these signaling pathways is involved in TGFbmediated apoptosis in RIE/Evi1 cells. As shown in Figure 5c , inhibition of p38 MAPK (by SB203580 or SB202190) had no effect on TGFb-mediated apoptosis in RIE/pBabe or RIE/Evi1 cells. Likewise, inhibition of JNK (SP600125) or MEK1/2 (U0126 or PD98059) had no significant effect on TGFb-mediated apoptosis. However, two inhibitors of PI3K (LY294002 and wortmanin) restored TGFb-mediated cell death in RIE/Evi1 cells. Thus, when RIE/Evi1 cells were treated with TGFb in the presence LY294002, TGFb promoted caspase 3 cleavage (Figure 5d 
( Figure 5e and f). Expression of dnSmad3 had no effect on taxol-mediated apoptosis (Figure 5e ), indicating that resistance to taxol is not due to loss of Smad3 function in RIE/Evi1 cells. The observation that Evi1 inhibits induction of apoptosis by physiological stimuli such as TGFb as well as pharmacological agents such as taxol, raised the question of the potential role of Evi1 in transformed intestinal epithelial cells.
Evi1 suppresses apoptosis in human colon cancer cell lines
Evi1 suppresses apoptosis in RIE cells, suggesting that the oncogenic potential of Evi1 may depend upon its ability to function as a survival gene in tumor cells. To explore this hypothesis, we screened a number of human colon cancer cell lines for expression of Evi1. As shown in Figure 6a , Evi1 protein was detected in HT-29 cells and, at lower levels, in Caco 2 cells. The abundance of Evi1 protein in HT-29 was significantly less than that observed in endometrial carcinoma HEC-1B cells, which are known to express very high levels of Evi1 (Morishita et al., 1990) . Evi1 mRNA was also abundant in HT-29 cells Figure 6b . Evi1 is located on human chromosome 3q26, and this region is known to be amplified in a number of carcinomas (Brass et al., 1996; Brooks et al., 1996; Racz et al., 1999) . Therefore, we used quantitative real-time PCR to measure Evi1 gene copy number in the human colon cancer cell lines. In parallel, we measured gene copy number of protein kinase C-iota (PKCi), which is also located on 3q26 near the Evi1 locus. As shown in Figure 6c , both the Evi1 and PKCi genes were significantly amplified in HT-29 cells, indicating that the 3q26 locus is amplified in these cells and suggesting Evi1 inhibits apoptosis by activation of PI3K/AKT signaling. (a) Extracts were prepared from mid-log phase cultures of RIE/pBabe or RIE/Evi1, and these extracts were blotted using antibodies against phosphorylated and total p38 MAPK, JNK, ERK1/ 2, or AKT. (b) RIE/pBabe or RIE/Evi1 cells were treated with 3 ng/ml TGF-b1 for 24 h, and proteins were extracted and assayed for total and phosphorylated ERK1/2 and AKT. (c) Cell death was assessed by ELISA measurement of nuclear histone release from RIE/ pBabe or RIE/Evi1 cultures treated with 3 ng/ml TGF-b1 for 24 h in the presence or absence of SB203580 (5 mM), SB202190 (5 mM), SP600125 (1 mM), U0126 (5 mM), PD98059 (5 mM), LY294002 (25 mM) or wortmanin (50 nM). (d) Cells were treated with vehicle or with 3 ng/ml TGF-b1 for 24 h in the presence of 25 mM LY294002. Proteins were extracted and Western blotting was carried out to measure caspase 3 cleavage. (e) RIE/pBabe, RIE/Evi1, or RIE/dnSmad3 cultures were treated with 10 nM taxol in the presence or absence of 25 mM LY294002 for 6 h. Cell death was determined by measurement of nuclear histone release. Bars represent the mean7s.d. of three replicate experiments. (f) Cells were treated with 10 nM taxol alone or with 25 mM LY294002 for 6 h. Proteins were extracted and caspase 3 cleavage was assessed by Western blotting.
Evi1 is a survival factor in intestinal epithelial cells Y Liu et al that overexpression of Evi1 in HT-29 cells is the result of gene amplification. We next asked if Evi1 is a survival gene in HT-29 cells. HT-29 cells are much more resistant to taxol than are RIE cells, making it necessary use 100 nM taxol for 48 h to measure significant nuclear histone release. However, HT-29 cells treated with LY294002 exhibited significantly more nuclear histone release when treated with taxol ( Figure 7a ). HT-29 cells express very low levels of the TGFb type II receptor (Winesett et al., 1996) , and, as a result, are resistant to TGFb-mediated apoptosis. As expected, LY294002 did not restore TGFb sensitivity to HT-29 cells (Figure 7a ). Consistent with the nuclear histone release data, LY294002 increased caspase 3 cleavage in taxol-treated HT29 cells (Figure 7b) indicating that PI3K activity confers resistance to taxolmediated apoptosis. Taxol alone had no significant effect on AKT expression or activity in HT-29 cells (Figure 7c ), whereas LY294002 effectively blocked AKT phosphorylation in the presence and absence of taxol. RNAi technology was used to determine if Evi1 inhibits apoptosis by a PI3K/AKT-dependent pathway in HT-29 cells. As shown in Figure 7d , shRNA against Evi1 reduced Evi1 protein expression by >80% with no effect on expression of PKCi. However, knockdown of shRNA expression constructs that correspond to GFP or Evi1. An aliquot of the transfected cells was harvested at 48 h. Extracts were prepared and assayed for expression of Evi1, PKCi, actin, phospho-AKT and total AKT. (e) The remaining shRNAtransfected HT-29 cells were treated with 3 ng/ml TGF-b1 (gray bars) or 100 nM taxol for 48 h (black bars). Nuclear histone release was measured as an indicator of cell death. (f) western blotting was used to confirm caspase 3 cleavage in taxol-treated HT-29 cells transfected with shGFP or shEvi1 expression vectors, as described above.
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Evi1 significantly inhibited AKT phosphorylation, demonstrating that Evi1 activates PI3K/AKT signaling in HT-29 cells, just as it does in RIE cells. To determine if knockdown of Evi1 expression increases the sensitivity of HT-29 cells to apoptotic stimuli, HT-29 cells transfected with shRNA expression vectors against GFP or Evi1 were treated with TGFb and apoptosis was measured (Figure 7e ). Evi1 knockdown had no effect on the resistance of these cells to TGFb. However, knockdown of Evi1 resulted in a significant increase in taxol sensitivity as measured by nuclear histone release (Figure 7e ) or caspase 3 cleavage (Figure 7f ). We conclude that in addition to the ability to inhibit Smadmediated signaling, Evi1 also functions as a survival gene by activating an antiapoptotic PI3K/AKT signaling pathway in both non-transformed intestinal epithelial cells and in colon cancer cells.
Discussion
A number of groups have shown that Evi1 inhibits classical Smad-mediated transactivation of reporter genes. However, the effects of Evi1 on cellular responses to TGFb have received less attention, particularly in non-hematopoietic cells. Alliston et al. (2005) showed that Evi1 inhibits induction of Smad7 in myoblasts, the first demonstration that Evi1 can inhibit induction of an endogenous gene by TGFb. Here we show that Evi1 also inhibits induction of PAI1 in intestinal epithelial cells. Since Evi1 potently inhibits TGFb-dependent transactivation of some classical target genes, such as PAI1, we expected Evi1 to block TGFb-mediated growth inhibition of RIE cells, just as Evi1 blocks TGFb-mediated growth inhibition in Mv1Lu cells (Kurokawa et al., 1998) . However, this prediction was not borne out. Since Evi1 inhibits induction of PAI1 by >90%, it seems unlikely that residual Smad activity in RIE/Evi1 cells is responsible for growth arrest. It is more likely that failure to observe growth inhibition is due to the mechanism that accounts for this response in RIE cells. In some cell types, TGFb inhibits growth by Smad3/ Sp1-dependent activation of the p15INK4B or p21Cip1 promoters (Feng et al., 2000; Pardali et al., 2000) . For example, in Mv1Lu cells TGFb-mediated growth arrest results from induction of p15INK4B (Hannon and Beach, 1994) . Evi1 blocks transactivation of p15INK4B promoter/reporter constructs (Feng et al., 2000) , and also blocks inhibition of [ 3 H]-thymidine incorporation in TGFb-treated Mv1Lu cells (Kurokawa et al., 1998) . Thus Evi1 blocks Smad-dependent induction of p15INK4B, thereby attenuating TGFb-mediated growth inhibition. However, p15INK4B is undetectable in RIE cells, even in the presence of TGFb. Instead, we have shown that TGFb-mediated growth inhibition of RIE cells is caused by inhibition of cyclin D1 expression (Ko et al., 1998) . Evi1 has no effect on TGFb-mediated inhibition of cyclin D1 expression, and, as a consequence, does affect TGFb-mediated growth arrest in intestinal epithelial cells.
Although Evi1 blocks induction of some TGFb target genes, such as PAI1, other TGFb-induced genes are not affected by Evi1. For example, Evi1 does not block induction of paxillin or integrina1. Consequently, Evi1 does not block TGFb-mediated activation of focal adhesion kinase, nor does Evi1 block induction of EMT by TGFb. Thus, intestinal epithelial cells that express Evi1 exhibit two major physiological responses to TGFb: growth inhibition and EMT. Interestingly, Evi1 is a potent inhibitor of TGFb-mediated apoptosis. This property of Evi1 appears likely to be integral to its oncogenic potential, since loss of response to apoptotic signals is one of the hallmarks of transformation.
We have shown that the apoptotic response to TGFb can be influenced by crosstalk between Smad3 and AKT (Conery et al., 2004) , and several reports indicate that activation of PI3K/AKT signaling suppresses TGFbmediated apoptosis (Chen et al., 1998 (Chen et al., , 1999 Shih et al., 2000) . Our data demonstrate that Evi1 activates PI3K/ AKT signaling, and suppresses TGFb-mediated apoptosis. However, the antiapoptotic effects of Evi1 are not limited to TGFb, since Evi1 also inhibits taxol-mediated cell death by a PI3K-dependent mechanism. Our results indicate that Evi1 functions as a survival factor in intestinal epithelial cells, and is likely to convey broad resistance to a number of physiological and pharmacological activators of apoptosis. Thus, the oncogenic effects of Evi1 may be inherent in the ability to activate PI3K and suppress apoptosis in transformed cells.
Evi1 resides at the 3q26 locus, which is known to be amplified in a number of solid tumors. This locus contains several potential oncogenes, in addition to Evi1, which may contribute to the transformed phenotype. For example, PKCi is located adjacent to Evi1 at this locus. We have shown that PKCi is an oncogene that is activated by amplification in squamous cell carcinoma of the lung (Regala et al., 2005a) . We have also shown that PKC plays a critical role in transformed growth (Zhang et al., 2004; Regala et al., 2005b) , but does not appear to function as a survival gene. In contrast, our present results show that Evi1 is a survival gene in human colon cancers that have undergone amplification of the 3q26 locus. Based on these observations, we hypothesize that Evi1 and PKCi may collaborate during colon carcinogenesis, with Evi1 suppressing apoptosis and PKCi stimulating transformed growth. Our data therefore identify Evi1 as a potential target for chemotherapy. Our results indicate that Evi1 may be overexpressed in a subset of human colon cancers, and that Evi1 might affect disease progression and/or sensitivity to chemotherapy. Current studies are focused upon evaluating the extent of 3q26 amplification in human colon cancers and assessing whether 3q26 amplification predicts sensitivity to chemotherapy and or survival of colon cancer patients.
Materials and methods
Cell culture and antibodies
Rat intestinal epithelium cells RIE-1 were maintained in DMEM supplemented with 5%FBS. Human colon cancer cell Cloning and construction of retroviral expression vectors Dominant-negative rat Smad3DSSVS in the pRK5 expression vector was obtained from Rick Derynck (University of California at San Francisco) and cloned into a pBabe/puro-3 derivative that encodes an N-terminal flag tag. This retrovirus was used to transform RIE-1 cells to puromycin resistance. Expression of dnSmad3 was confirmed by immunoblotting with flag antibodies, and function of dnSmad3 was confirmed by suppression of transient activation of the 3TP/luc TGFb reporter. Full-length human Evi1 cDNA was cloned from mRNA extracted from a human colon tumor. Doublestranded cDNA was synthesized using Clonetech SMART cDNA technology, according to the manufacturer's suggested protocols. Evi1 cDNA was amplified from double-stranded cDNA using primers that amplify from the translation start site in exon 3 (5 0 GCTTCTGCTGTTCATGAAGAGC) through the stop codon in exon 16 (5 0 GTCAACCTTGA TAACGTCATAC). The PCR products were cloned into pRK5 and the identity of the human Evi1 cDNA was confirmed by sequencing. In parallel, the Evi1 coding sequence was inserted into a pBabe/puro-3 derivative that encodes an Nterminal flag tag. Protocols for virus production and infection were obtained from the laboratory of Gary Nolan at Stanford University http://www.stanford.edu/group/nolan/retroviral_-systems/phx.html. RIE-1 cells were infected with pBabe/ flagEvi1 or empty pBabe/puro-3, and populations of stable transformants were selected for the ability to grow in 5 mg/ml puromycin. Evi1 expression in RIE/Evi1 populations was confirmed by immunoblot analysis.
Quantitative real-time RT-PCR Total RNA or genomic DNA was isolated using Ambion RNAqueous or Qiagen DNA Mini kits. QPCR was carried out using target-specific probes and primers obtained from PE Applied Biosystems (ABI). Primers and reporters for rat cyclin D1, integrina1, PAI1, and GAPDH mRNA and for human Evi1 and PKCi genomic DNA were obtained using the ABI Assay by Design procedure. The sequences of these reagents are shown in Table 1 . The reagents used to measure human Evi1 and GAPDH mRNA were obtained from the ABI Assay on Demand catalog, and the context sequence against which these primers and reporters are directed is also shown in Table 1 . Reagents used to measure rat and human 18S RNA and human RNaseP were obtained from the Assay on Demand catalog, and the context sequences of these reagents may be obtained from the ABI web site. All QPCR reagents were validated by demonstrating a linear relationship between sample concentration and amplification kinetics over a three log range of nucleic acid concentrations, using cDNA made from total RNA or genomic DNA from reference samples and normalizing to 18S RNA (DC T ¼ C Ttarget À C T18S ) for mRNA and RNaseP (DC T ¼ C Ttarget À C TRNaseP ) for genomic DNA. Taqman Universal Master Mix (ABI) was used for PCR reactions and amplification data were collected using an ABI Prism 7900 Sequence Detector and analysed using the Sequence Detection System software (SDS V2.0) from ABI. All QPCR reagents were validated by demonstrating a slope of 070.1 when DC T was plotted against log 10 nucleic acid concentration Unless stated otherwise, the abundance of mRNA was calculated by normalization to GAPDH (DC T ¼ C Ttarget À C TGAPDH ) and calibrated to mRNA abundance in untreated RIE/pBabe cells (DDC T ¼ DC T cell line À DC T RIE=pBabe ). Data are represented as 2 ÀDDCT , such that the abundance of the individual mRNAs in RIE/pBabe is expressed as 1.0 (DC T RIE=pBabe À DC T RIE=pBabe ¼ 0, and 2 À0 ¼ 1.0). The abundance of Evi1 mRNA in colon cancer cells was normalized to GAPDH and calibrated to HCT116 cells. Evi1 and PKCi gene copy number in human colon cancer cell lines was normalized against RNaseP and calibrated to Evi1 gene copy number in HCT-15. Statistical analysis for QPCR and other results was carried out using the Mann-Whitney Rank Sum analytical function of Sigma Stat 32 (Table 2) .
Immunocytochemistry analysis of actin stress fiber formation during EMT RIE cells cultured on cover glasses (Fisher Scientific) were fixed in 3% paraformaldehyde for 30 min, blocked with 3% nonfat milk in PBS for 10 min, and incubated with Texas Red-X phalloidin (Molecular Probes) for 30 min in the dark. The cover glasses were then washed three times with PBS and mounted on glass slides (Fisher Scientific) using Aqua Poly/ Mount (Polysciences). Fluorescence images were captured using a Leica DM5000 microscope and compiled into Adobe Photoshop. Evi1 is a survival factor in intestinal epithelial cells Y Liu et al
